Table 6. Clinical measures for patients discharged alive and dead.
| Demographics | Death | Discharge |
| Age, mean (range) y | 64.6 (34-78) | 47.04 (18-70) |
|
Male (%) Female (%) |
60% 40% |
60%
40% |
| Chronic medical illness (%) | 40% | 57.8% |
| hypertension | 20% | 24.4% |
| diabetes | 20% | 33.3% |
| Cardiovascular disease | 0% | 13.3% |
| Cerebrovascular disease | 0% | 2.2% |
| malignancy | 20% | 4.4% |
| Respiratory system disease | 0% | 13.3% |
| Chronic kidney disease | 20% | 2.2% |
| Endocrine system disease | 20% | 2.2% |
| nervous system disease | 0% | 2.2% |
| autoimmune system disease | 0% | 2.2% |
| hematologic system disease | 0% | 2.2% |
| Antihypertensive drug | ||
| taking ARB medication | 0% | 15.6% |
| Vital sign at presentation, median | ||
| Temperature, °C | 37.7 | 37 |
| Respiratory rate, breaths/min | 20 | 16 |
| Pulse oximeter O2 saturation, % | 91 | 96 |
| Systolic blood pressure, mm Hg | 119.5 | 120 |
| Diastolic blood pressure, mm Hg | 79.50 | 70 |
| Heart rate, /min | 85.50 | 86.50 |
| Blood routine, median (range) | ||
| Leucocytes (× 103 per µl); normal range: 3.5–9 | 5.70 | 5.90 |
| Neutrophils (%); normal range: 40-70 | 73 | 70.55 |
| Lymphocytes (%); normal range: 20-50 | 15.10 | 20.15 |
| Platelets (× 103 per µl); normal range: 150–450 | 160 | 177 |
| Hemoglobin (g/dl); normal range: 13.5-18 | 11.50 | 12.65 |
| Coagulation function | ||
| Prothrombin time (s); normal range: 12-14 | 12.85 | 13.20 |
| partial thromboplastin time (s; normal range 25-45 | 37.50 | 32.50 |
| International Normalized Ratio (S) | 1.05 | 1.10 |
| Blood biochemistry, median(range) | ||
| Alanine aminotransferase (U/L); normal range :up to 41 | 28 | 31 |
| Aspartate aminotransferase (U/L); normal range: up to 37 | 49 | 34.50 |
| alkaline phosphatase(U/L); normal range: 98- 279 | 162 | 156 |
| Total bilirubin (mg/dl); normal range: 0.1–1.2 | 0.8 | 0.75 |
| Serum creatinine (mg/dl); normal range: 0.6-1.3 | 1.20 | 0.9 |
| Urea( mg/dl); normal range: 11-55 | 52 | 32.50 |
| Lactate dehydrogenase (U/L); normal range: 120–460 | 663 | 472 |
| Glucose (mg/dl; normal range<140) | 97 | 93.5 |
| Troponin I (ng/l); normal range <19 (n=10) | 29.20 | 5 |
| Creatine phosphokinase (cpk) (mg/dl); normal range 24-195 (n=5) | 501 | 119.5 |
| Ferritin (ng/ml); normal range: 4.63-204 (n=8) | 2560 | 569.16 |
| Infection-related biomarkers | ||
| Erythrocyte sedimentation rate (mm/h); normal range: 0.0–15.0 | 52 | 36 |
| C-reactive protein (qualitative); normal range: 0 | 1.50 | 3 |
| Chest CT Findings (%) | ||
| Ground glass opacity & consolidation mix | 100% | 82.2% |
| Just Ground glass opacity | 0% | 2.2% |
| Just consolidation | 0% | 8.9% |
|
Location of consolidation Upper lobe Lower lobe Both lobe Unilateral bilateral |
0% 0% 100% 20% 80% |
4.4% 31.1% 55.6% 15.6% 73.3% |
|
Location of ground glass opacity Upper lobe Lower lobe Both lobe Unilateral Bilateral |
0% 0% 100% 0% 100% |
0% 6.7% 77.8% 0% 82.2% |
| Unilateral Plural effusion | 0% | 2.2% |
| Plural thickening | 0% | 4.4% |
| Treatment (%) | ||
| Oxygen Therapy | 80% | 73.3% |
| Mechanical ventilation | 60% | 0% |
| Antibiotic treatment | 100% | 97.8% |
| Antiviral treatment | 80% | 86.7% |
| Hydroxychloroquine | 100% | 95.6% |
| Acetaminophen | 100% | 64.4% |